コンテンツへスキップ
Merck
  • Comparison of two Gram stain point-of-care systems for urogenital gonorrhoea among high-risk patients: diagnostic accuracy and cost-effectiveness before and after changing the screening algorithm at an STI clinic in Amsterdam.

Comparison of two Gram stain point-of-care systems for urogenital gonorrhoea among high-risk patients: diagnostic accuracy and cost-effectiveness before and after changing the screening algorithm at an STI clinic in Amsterdam.

Sexually transmitted infections (2014-05-27)
M Bartelsman, M Straetemans, K Vaughan, S Alba, M S van Rooijen, W R Faber, H J C de Vries
要旨

To compare point-of-care (POC) systems in two different periods: (1) before 2010 when all high-risk patients were offered POC management for urogenital gonorrhoea by Gram stain examination; and (2) after 2010 when only those with symptoms were offered Gram stain examination. Retrospective comparison of a Gram stain POC system to all high-risk patients (2008-2009) with only those with urogenital symptoms (2010-2011) on diagnostic accuracy, loss to follow-up, presumptively and correctly treated infections and diagnostic costs. Culture was the reference diagnostic method. In men the sensitivity of the Gram stain was 95.9% (95% CI 93.1% to 97.8%) in 2008-2009 and 95.4% (95% CI 93.7% to 96.8%) in 2010-2011, and in women the sensitivity was 32.0% (95% CI 19.5% to 46.7%) and 23.1% (95% CI 16.1% to 31.3%), respectively. In both periods the overall specificity was high (99.9% (95% CI 99.8% to 100%) and 99.8% (95% CI 99.7% to 99.9%), respectively). The positive predictive value (PPV) and negative predictive value (NPV) before and after 2010 were also high: PPV 97.0% (95% CI 94.5% to 98.5%) and 97.7% (95% CI 96.3% to 98.6%), respectively; NPV 99.6% (95% CI 99.4% to 99.7%) and 98.8% (95% CI 98.5% to 99.0%), respectively. There were no differences between the two time periods in loss to follow-up (7.1% vs 7.0%). Offering Gram stains only to symptomatic high-risk patients as opposed to all high-risk patients saved €2.34 per correctly managed consultation (a reduction of 7.7%). The sensitivity of the Gram stain is high in men but low in women. When offered only to high-risk patients with urogenital symptoms, the cost per correctly managed consultation is reduced by 7.7% without a significant difference in accuracy and loss to follow-up.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
クリスタルバイオレット溶液 溶液, 1%, aqueous solution
Sigma-Aldrich
クリスタルバイオレット, certified by the Biological Stain Commission
Sigma-Aldrich
クリスタルバイオレット, ACS reagent, ≥90.0% anhydrous basis
Sigma-Aldrich
クリスタルバイオレット溶液 溶液
Sigma-Aldrich
アジスロマイシン
Sigma-Aldrich
セフトリアキソン 二ナトリウム塩 ヘミ(七水和物), third-generation cephalosporin antibiotic
Sigma-Aldrich
クリスタルバイオレット溶液 溶液
USP
アジスロマイシン, United States Pharmacopeia (USP) Reference Standard
USP
セフトリアキソン 二ナトリウム塩 ヘミ(七水和物), United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
クリスタルバイオレット, for microscopy (Bact., Bot., Hist., Vit.), indicator (pH 0.1-2.0)
Supelco
アジスロマイシン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
クリスタルバイオレット, VETRANAL®, analytical standard
Supelco
セフトリアキソン 二ナトリウム塩 ヘミ(七水和物), Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
ゲンチアナバイオレット 溶液
Sigma-Aldrich
Gentian Violet, meets USP testing specifications
Sigma-Aldrich
クリスタルバイオレット, JIS special grade
USP
アジスロマイシン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
クリスタルバイオレット, indicator for the determination of the redox potential, S. No.: 785
Sigma-Aldrich
グラム・ハッカー染色液(I)
アジスロマイシン 二水和物, European Pharmacopoeia (EP) Reference Standard
セフトリアキソン 二ナトリウム塩 ヘミ(七水和物), European Pharmacopoeia (EP) Reference Standard
システム適合性用アジスロマイシン, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
クリスタルバイオレット, SAJ first grade
クリスタルバイオレット, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
クリスタルバイオレット, SAJ special grade
システム適合性用メチルロザニリン, European Pharmacopoeia (EP) Reference Standard
アジスロマイシン 二水和物, European Pharmacopoeia (EP) Reference Standard